Company intelligence / Profile preview

Beijing Falikang Pharmaceutical

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Falikang distributes roxadustat (oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase) in China for anemia associated with chronic kidney disease. Roxadustat is included on China’s National Reimbursement Drug List; sales and hospital listings have expanded nationwide. An approval decision for chemotherapy-induced anemia is anticipated in 2024.

Therapeutic areas: HematologyNephrology
Modalities: Small molecule
Industry: Biotech

Partnerships

AstraZeneca (joint venture for sales & marketing in China)FibroGen (manufacture and supply of roxadustat)

Beyond the preview

Go deeper on Beijing Falikang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Falikang Pharmaceutical.

Explore the full profile